Searched for
GAVIS PHARMACEUTICALS
Lack of access to cost-effective Indian vaccines straining Pakistan's economy: MinisterPakistan faces economic strain as affordable vaccine imports from India ceased after a May 2025 conflict. This halt impacts the nation's ab...- Governments pledge $8.8 billion for global vaccines allianceThe online meeting beat a target to raise $7.4 billion to provide vaccines at a much reduced cost to 300 million children worldwide over th...
- Lupin Q3 results: Loss widens to Rs 835 crore on higher taxTax expenses for the quarter jumped to Rs 767 crore from Rs 245.40 crore.
- Lupin CFO quits, to pursue opportunities outside pharmaSwaminathan as the CFO of Lupin, was part of some of company's biggest mergers and acquisition in US and Japan
- Lupin net skids, says Gavis deal ‘shy’ of expectationsThe business fell 13.2% to Rs 1,900.7 crore from a year earlier and contributed 46% of sales.
- Lupin gets USFDA nod for generic pain relieving drugAs per IMS MAT sales data, Hydrocodone Bitartrate and Acetaminophen tablets had sales of USD 89.6 million in the US market.
- Lupin arm gets tentative FDA nod for anti-bacterial drugGavis has received tentative approval for its Azithromycin for oral suspension USP from the USFDA, Lupin said in a BSE filing.
- Lupin looks to launch 25 products in US this fiscalIn the current year, apart from the Gavis portfolio, Fortamet and Glumetza, the company expects to launch products like Minastrin and Epzic...
- GAVIS Pharma LLC looking to exit Bengaluru-based Wintac LtdGavis Pharma LLC is now exploring options to exit its listed Indian arm. Wintac Ltd was not part of the 2015 deal struck between Lupin & Ga...
- Lupin gets USFDA nod for fungal infection drugThe company's products are generic versions of PF Prism C.V's Vfend tablets and Vfend oral suspension in the same strengths, report added.
- Lupin nosedives 8% even as drugmaker reports 47% PAT growth in Q4The company had reported PAT of Rs 547 crore in the same quarter last financial year.
- Lupin launches generic insomnia drug in USDrug major Lupin has launched a generic insomnia drug, Zolpidem Sublingual tablets, in the US market with 180-days of marketing exclusivity.
- Lupin completes acquisition of GAVIS PharmaThe acquisition enhances the company's scale in the US generic market and also broadens its pipeline in dermatology and controlled substanc...
- Lupin to invest in Japan; eyes 20 launchesLupin, one of India's top five pharmaceutical companies, is planning to make significant investments in Japan, the second biggest pharmaceu...
- Lupin, Gavis to sell 2 drugs to fulfil US FTC conditionThe acquisition creates the fifth largest portfolio of abbreviated new drug application (ANDA) filings with the USFDA, addressing a USD 63....
- JPMorgan to fund Lupin’s $880-million Gavis dealThe loan, it’s understood, is not backed by hard collateral or claims on future cashflow, but based on pure credit assessment.
- Lupin falls on lower sales guidance for FY16Lupin’s move to acquire Gavis Pharmaceuticals for $880 million, approximately Rs 5600 crore, is seen as a long-term positive.
- Lupin buys US generics firm Gavis for Rs 5606 croreThe deal, which is cash-free and debt-free, widens the company's pipeline in dermatology and controlled substance products, Lupin said.
- Controversial vaccine studies: Why is Bill & Melinda Gates Foundation under fire from critics in India?Bill & Melinda Gates Foundation has funded two entities that have played a key role in the immunization programme and are both under fire f...
- Global vaccine campaign plans to raise $3.7 billion for immunisationThe Global Alliance for Vaccine Immunization, cofounded by the Bill & Melinda Gates Foundation, will create an advocacy group to raise $3.7...
Load More
